MedTrace Logo

Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients

NCT02946671 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-03-06

No results posted yet for this study

Summary

To assess the safety of preoperative combination therapy with KW-0761 (anti-CCR4) and ONO-4538 (anti-PD-1).

To assess the behavior of immune cells in peripheral blood and tumor.

Conditions

Interventions

BIOLOGICAL

Mogamulizumab

Mogamulizumab (0.1, 0.3 or 1.0 mg/kg) is administered.

BIOLOGICAL

Nivolumab

Nivolumab (3.0 mg/kg) is administered.

Sponsors & Collaborators

  • Kyowa Kirin Co., Ltd.

    collaborator INDUSTRY

  • Ono Pharmaceutical Co. Ltd

    collaborator INDUSTRY

  • Clinical Study Support, Inc.

    collaborator UNKNOWN

  • Fiverings Co., Ltd.

    collaborator OTHER

  • Osaka University

    lead OTHER

Principal Investigators

  • Hisashi Wada, M.D., Ph.D · Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02946671 on ClinicalTrials.gov